ArticleCureus2025
A Rare Presentation in a Common Renal Anomaly: Metastatic Adenocarcinoma in a Horseshoe Kidney.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Horseshoe kidney is the most common renal fusion anomaly, occurring in approximately 1 in 500 individuals. While renal cell carcinoma (RCC) is the most frequently reported malignancy in horseshoe kidneys, primary adenocarcinoma of the renal pelvis is exceedingly rare, accounting for less than 1% of all renal malignancies. Due to its rarity and nonspecific presentation, diagnosis is often delayed, leading to poor prognosis. We report the case of a 35-year-old male who presented with progressive abdominal pain and backache for three months. Initial imaging, including radiography, ultrasound, and contrast-enhanced computed tomography (CT), revealed a horseshoe kidney with a heterogeneously enhancing mass arising from the left renal pelvis, containing coarse calcifications. Further evaluation with magnetic resonance imaging (MRI) and fluorodeoxyglucose (FDG) positron emission tomography (PET) demonstrated metastatic involvement of the dorsal vertebrae (D4, D8) and first lumbar vertebra (L1), along with pulmonary metastases. CT-guided biopsy confirmed primary adenocarcinoma of the renal pelvis. Next-generation sequencing (NGS) did not reveal actionable mutations, limiting the role of targeted therapy. The patient was managed with systemic chemotherapy and palliative radiotherapy for bone metastases. This case underscores the importance of multimodal imaging for accurate diagnosis and staging, as well as the role of molecular profiling in treatment planning. Given the poor prognosis associated with metastatic disease, further research into the molecular characteristics and targeted therapies for this rare malignancy is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.